Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.46 estudios en Nefrología e hipertensión (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Evaluation of the Total Kidney Volume AI Algorithm Rochester, Minn. The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of cysts within the kidneys. ADPKD is a leading cause of end-stage renal disease. Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD. Accurate, MR based kidney volume measurements are the best parameter for following the progression of ADPKD, and are suggested be acquired to measure progression and effects of Tolvaptan. However, making these slice-by-slice volume measurements can be extremely time consuming when done manually. The purpose of this work is to evaluate an AI algorithm to make the measurements. The results of the algorithm will be reviewed by a qualified radiologist familiar with the algorithm’s results. If the radiologist agrees with the results, kidney volumes (left, right and combined) will be recorded for clinical use. The usage of the algorithm in this setting (with review by radiologist, and manual correction) is a minimal risk to the patients: a failure of the algorithm will have no impact on treatment and errors will be caught and corrected by the QC process. Because the algorithm will not be used solely for diagnosis or inform treatment without the confirmation of the diagnosis by another, medically established diagnostic product or procedure this study constitutes minimal risk to patients. TruGraf® Long-term Clinical Outcomes Study Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate post-transplant clinical outcomes in receipients of kidney transplants who are undergoing TruGraf® and TRAC™ monitoring. Monogenic Kidney Stone - Genetic Testing Rochester, Minn. 90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff. A Study to Determine the Incidence of Atrial and Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy Rochester, Minn. The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients Rochester, Minn. The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension). Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 33 Ir a página 44 Ir a página 55 A continuación, se enumeran los ensayos clínicos actuales.46 estudios en Nefrología e hipertensión (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study to Determine the Incidence of Atrial and Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy Rochester, Minn. The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea. Evaluation of the Total Kidney Volume AI Algorithm Rochester, Minn. The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of cysts within the kidneys. ADPKD is a leading cause of end-stage renal disease. Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD. Accurate, MR based kidney volume measurements are the best parameter for following the progression of ADPKD, and are suggested be acquired to measure progression and effects of Tolvaptan. However, making these slice-by-slice volume measurements can be extremely time consuming when done manually. The purpose of this work is to evaluate an AI algorithm to make the measurements. The results of the algorithm will be reviewed by a qualified radiologist familiar with the algorithm’s results. If the radiologist agrees with the results, kidney volumes (left, right and combined) will be recorded for clinical use. The usage of the algorithm in this setting (with review by radiologist, and manual correction) is a minimal risk to the patients: a failure of the algorithm will have no impact on treatment and errors will be caught and corrected by the QC process. Because the algorithm will not be used solely for diagnosis or inform treatment without the confirmation of the diagnosis by another, medically established diagnostic product or procedure this study constitutes minimal risk to patients. TruGraf® Long-term Clinical Outcomes Study Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate post-transplant clinical outcomes in receipients of kidney transplants who are undergoing TruGraf® and TRAC™ monitoring. Monogenic Kidney Stone - Genetic Testing Rochester, Minn. 90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients Rochester, Minn. The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension). Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 33 Ir a página 44 Ir a página 55 Solicite una consulta Conocimientos y categoríasInvestigación Oct. 14, 2023 Comparte en: FacebookTwitter Nefrología e hipertensiónSeccionesSolicita una consultaPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónHistorias de pacientesCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicita una consultaPanorama generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónHistorias de pacientesCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20464466 Centros y departamentos médicos Nefrología e hipertensión